Abstract 25
Hepatitis C virus (HCV) is a major cause of liver disease. Spontaneous resolution of infection is 26 associated with broad, MHC class I-(CD8 + ) and class II-restricted (CD4 + ) T cell responses to 27 multiple viral epitopes. Only 20% of patients clear infection spontaneously, however, most develop 28 chronic disease. The response to chemotherapy varies; therapeutic vaccination offers an additional 29 treatment strategy. To date, therapeutic vaccines have demonstrated only limited success in clinical 30 trials. Vector-mediated vaccination with multi-epitope-expressing DNA constructs provides an 31 improved approach. Highly-conserved, HLA-A2-restricted HCV epitopes and HLA-DRB1-restricted 32 immunogenic consensus sequences (ICS, each composed of multiple overlapping and highly 33 conserved epitopes) were predicted using bioinformatics tools and synthesized as peptides. HLA 34 binding activity was determined in competitive binding assays. Immunogenicity and the ability of 35 each peptide to stimulate naïve human T cell recognition and IFN-γ production were assessed in 36 cultures of total PBMCs and in co-cultures composed of peptide-pulsed dendritic cells (DCs) and 37 purified T lymphocytes, cell populations derived from normal blood donors. Essentially all predicted 38 HLA-A2-restricted epitopes and HLA-DRB1-restricted ICS exhibited HLA binding activity and the 39 ability to elicit immune recognition and IFN-γ production by naïve human T cells. The ability of DCs 40 pulsed with these highly-conserved HLA-A2-and -DRB1-restricted peptides to induce naïve human 41
Introduction 46 Hepatitis C virus (HCV), a small single-stranded RNA virus, constitutes a major cause of liver 47 disease [1] . The positive-sense genome encodes an ~3,000 amino acid poly-protein precursor, 48 which is cleaved by cellular and viral proteases to yield three structural [core, envelope 1 (E1) and 49 E2], and seven nonstructural (p7, NS2, NS3, NS4a, NS4b, NS5a and NS5b) proteins [2] . 50
Spontaneous resolution of HCV infections is associated with broad, MHC class I-(CD8 + ) and class 51 II-restricted (CD4 + ) T cell responses to multiple viral epitopes derived from these proteins [3, 4] . 52
Unfortunately, only 20% of patients clear infection spontaneously, most develop chronic disease [5] . 53
Seventy to eighty percent of patients infected with HCV genotype 1 (the principal causative agent of 54 hepatitis C in the U.S.) experience a sustained virologic response (SVR) following treatment that 55 includes protease inhibitors, i.e., telaprevir or boceprevir, administered in conjunction with 56 PEGylated interferon and ribavirin. A significant number of those treated remains infected, however, 57 the cost of treatment is high, and the risk and severity of side effects are considerable [6, 7] . New 58 approaches to treating chronic HCV infections are urgently needed. 59 Therapeutic vaccination concurrent with or without drug therapy offers an additional approach 60 to treating chronic hepatitis C. Indeed, the capacity of a significant percentage of patients to resolve 61 acute infections spontaneously suggests that an effective therapeutic vaccine is a realistic goal. A 62 safe and effective vaccine must elicit broad, vigorous CD4 + and CD8 + T cells responses to 63 conserved viral epitopes, which culminate in the elimination of HCV without causing liver pathology. Vaccination with HCV epitope expressing dendritic cells (DCs) offers a vector-mediated 69 approach to treating chronic, HCV infected patients. DCs play a central role in CD4 + and CD8 + T cell 70 activation and the induction of immunity [11] . The potential effectiveness of DC-based vaccines in 71 treating chronic hepatitis C has been demonstrated in animal models [12] [13] [14] . Moreover, in a recent 72 Phase I clinical trial, chronically-infected patients vaccinated with monocyte-derived DCs pulsed with 73 6 HCV-specific, HLA-class I-restricted peptides exhibited peptide-specific CD8 T cell responses [15] . 74
These responses were not sustained, however, and there was no effect on viral load suggesting that 75 HCV clearance might require vaccination with DCs that expressed a broader range of viral epitopes. 76
Toward this end, immunoinformatics tools were used to predict 21 HLA-A*0201-restricted epitopes 77 and 19 HLA-DRB1-restricted immunogenic consensus sequences (ICS, each composed of multiple 78 epitopes), which were highly-conserved and encoded by HCV genotype 1. These predicted 79 epitopes/ICS were synthesized as peptides and their capacities to bind HLA molecules were 80 determined. Subsequently, their immunogenicity and ability to elicit the peptide-specific responses of 81 naïve human T cells were validated in an in vitro peripheral blood mononuclear cell (PBMC) 82 immunogenicity assay. Similarly, monocyte-derived DCs pulsed with these same peptides induced 83 the epitope-specific responses of naïve CD4 + and CD8 + T cells in culture demonstrating the potential 84 efficacy of a multi-epitope-based HCV vaccine that targets dendritic cells. 85 86 87 88
Materials and Methods

88
Genome Collection 89
Hepatitis C viral sequences marked complete, representing a total of 871 genotype 1a and genotype 90 1b polyproteins, were acquired from the Los Alamos sequence and immunology database [16, 17] . 91
Conserved 9-mer search 92
Nine-mer amino acid sequences, constituting the length of the peptide chain that fits into the binding 93 groove of the HLA class I and class II molecules, were parsed out of the polyproteins and compared 94 for identical parsed 9-mers in matching open reading fames of other genotype 1a or 1b isolates 95 using the Conservatrix algorithm [18] . The potential immunogenicity of these identical 9-mer 96 sequences was predicted using the computational method described below. 97
Epitope mapping 98
Approximately 50% of the population residing in the U.S. expresses cell-surface HLA-A2; essentially 99 the entire population expresses one or more HLA-DRB1 alleles [19, 20] . Consequently, each 9-mer 100 was scored for its predicted potential to bind a panel of eight HLA-DRB1 alleles (DRB1*0101, 101 DRB1*0301, DRB1*0401, DRB1*0701, DRB1*0801, DRB1*1101, DRB1*1301 and DRB1*1501) 102
using EpiMatrix, a matrix-based algorithm for mapping T cell epitopes [21, 22] . Additionally, all 103 parsed 9-mers were scored for the potential to bind HLA-A2. Putative HLA-A2 epitopes were 104 selected based on conservation in genotype 1a and b, EpiMatrix HLA A2-matrix predicted binding 105 score, and reports of the ex vivo response of PBMCs obtained from HCV-infected patients. 106
Immunogenic consensus sequences 107
HLA-DRB1-restricted ICS were constructed using EpiAssembler, an algorithm that maximizes 108 epitope density by assembling potentially immunogenic 9-mers (identified using EpiMatrix) into 18-109 25 amino acid stretches [23]. To avoid potential cross-reactivity with the human proteome, any 110 peptide that shared more than 7 identities per 9-mer frame was eliminated from further consideration 111
[24]. The final HLA-A2-and -DRB1-restricted peptide sequences were synthesized using 9-112 fluoronylmethoxycarbonyl chemistry and purified >85% by 21 st Century Biochemicals 113 (Marlboro, MA).
114
HLA Binding Assay 115
The capacity of predicted epitopes (peptides) to bind multiple HLA-DRB1 alleles was assessed 116 using a competitive, HLA class II binding assay as we described previously [24,25], using HLA 117 molecules obtained from Bill Kwok, Benaroya Research Institute, Seattle, WA). Assays were 118 performed for HLA-DRB1*0101, -DRB1*0301, -DRB1*0401, -DRB1*0701, -DRB1*1101 and -119 DRB1*1501, alleles that provide broad representation of HLA class II that are prevalent in human 120 populations [20] . IC 50 values were estimated and the predicted peptides were classified as exhibiting 121 very high (< 1 µM), high (1 µM -10 µM), moderate (10 µM -100 µM) or low (>100 µM) affinity. 122
Peptides that exhibited very high, high or moderate affinity were considered binders (a more detailed 123 classification is provided in the results section). 124
The ability of predicted epitopes to bind HLA-A*0201 was assessed using a fluorescence 125 polarization-based competitive peptide-binding assay according to published methods [26] . The 126 concentration of experimental peptide that inhibited 50% binding of the FITC-labeled reference 127 peptide (IC 50 ) was determined. Experimental peptides were considered: high (IC 50 <5 µM), moderate 128 (5 µM<IC 50 <50 µM) and low (IC 50 = 50 -100 µM) affinity binders. Peptides that failed to demonstrate 129 dose-dependent inhibition or exhibited an IC 50 >100 µM were considered non-binders. 130
Human subjects 131
Whole-blood leukocyte reduction filters (blood filters; Sepacell RZ-2000, Baxter Healthcare 132
Corporation, Irvine CA) were obtained from the Rhode Island Blood Center (Providence, RI). These 133 used, de-identified filters contain white cells derived from blood donated with informed consent by 134 healthy volunteers. The Lifespan Institutional Review Board (Rhode Island Hospital) approved this 135 study. 136
Peripheral blood mononuclear cell (PBMC) recovery and purification 137
PBMCs were recovered from blood filters according to the methods of Meyer et al. [27] . Filters 138 obtained within a 4-hour period following the leukocyte depletion step were back-flushed at room 139 temperature with Ca-and Mg-free Hank's basic salt solution containing sodium-EDTA and sucrose. 140
The recovered leucocytes were purified by centrifugation on Ficoll-Paque Plus (1.077; Pharmacia, 141
Uppsala, Sweden) gradient. All donors expressed HLA-A*0201 and HLA-DRB1. 142
Naïve PBMC cultures 143
The peptide-specific responses of naïve human T cells were induced by culturing purified PBMCs 
DC priming of naïve T cell ex vivo 159
Monocyte-derived DCs were generated in vitro in accordance with methods described by others 160
[29]. CD14 + monocytes were purified from PBMCs back-flushed from blood filters using anti-CD14- of medium was removed, 6 x 10 5 naïve T lymphocytes (derived from the population purified and 174 frozen above)/100 µl X-VIVO medium were added to each well; and the cells were co-cultured. 175
To quantify the epitope-specific responses of purified T cells co-cultured with peptide-pulsed 176
DCs, the cells were collected after 14 days incubation, centrifuged and resuspended in fresh X-VIVO 177 15 medium. The cells (50,000/100 µl) were transferred to IFN-γ capture antibody-coated ELISpot 178 plates that contained 5,000 mature DCs/100 µl X-VIVO 15/well generated as described in the 179 previous section and pulsed with the same peptide present during the initial co-culture period. The 180 remainder of the assay was conducted according to the supplier's protocol referenced in the 181 preceding section. 182
183
Results
184
Epitope/ICS predictions 185
A set of 21, HLA-A*0201-restricted epitopes were selected for synthesis from a set of more than 100 186 highly conserved, high-scoring peptides predicted using the EpiMatrix and Conservatrix algorithms 187 (Table I) . Twenty of these epitopes scored in the top 1% (Z score ≥2.32) and one (peptide ID# 13) 188 scored in the top 5% (Z score ≥1.64) of predicted binders, indicating a very high probability of HLA-189
A*0201 binding. The amino acid sequence, A*0201 EpiMatrix Z Scores and relative conservation of 190 these peptides among HCV genotypes 1a and 1b isolates (calculated using Conservatrix) are shown 191
in Table II . 192
Twenty-five HLA-DRB1-restricted ICS from the input HCV genotype 1a and 1b sequences 193 were selected from a list of 79 that were predicted using the EpiAssembler algorithm; these varied 194 from 15 to 27 amino acids in length. Each was composed of multiple, overlapping 9-mers (epitopes) 195 capable of binding more than one HLA-DRB1 allele. The number of epitopes contained within each 196 ICS predicted to bind across all 8 alleles was determined and ranged from 5 to 28 epitopes/ICS. 197
Among the original 25 ICS, three exhibited significant homology to sequences found in the human 198 genome and three overlapped protein junctions located within the HCV poly-protein; these six ICS 199
were excluded from further study. The amino acid sequence, HLA-DRB1 EpiMatrix Z scores, 200 number of predicted epitopes and conservation of the 19 remaining ICS among HCV genotypes 1a 201 and 1b isolates are shown in Table II . 202
Binding analyses 203
Each predicted epitope/ICS was synthesized. HLA binding affinity and concurrence with 204 computational predictions were determined. Positive predictions were defined as epitope scores 205 ≥1.64 on the EpiMatrix Z-scale and HLA binding of IC50<100µM. Overall, the proportion of 206 predictions that concurred with binding was ~90% (19/21) and 84% (96/114) for the HLA-A*0201-207 restricted peptides (Table III) and HLA-DRB1-restricted ICS (Table IV) , respectively. We expect no 208 more than three to five percent of randomly selected peptides to bind to any given HLA. In the 209 current case, approximately 85% of all predictions were confirmed, consistent with our previous 210 experience. The small number of negative predictions present in this dataset makes statistical 211 validation of the correlation between predicted binding and observed results difficult. We suggest 212 that the correlation between prediction and observed outcome is self-evident. 213
Epitope/ICS validation. 214
All predicted A2-restricted epitopes and DRB1-restricted ICS that exhibited HLA binding affinity 215 induced naïve T cell reactivity and IFN-γ production ex vivo, validating their immunogenicity. 216
PBMCs obtained from healthy blood donors and cultured 14 days in the presence of single peptides 217 subsequently exhibited peptide-specific IFN-γ production in ELISpot assays (Figure 1 proteins exhibited a temporary reduction in viral load [37] . 250
Therapeutic vaccination with HCV epitope-expressing DCs concurrent with or without 251 chemotherapy offers an additional vector-mediated approach to treating chronic, HCV-infected 252 patients. The utility of this approach is supported by clinical trials demonstrating tumor regression 253 and long-term survival in a subset of cancer patients administered antigen-pulsed DCs [38] . Indeed, 254 These authors acknowledge a potential conflict of interest and attest that the work contained in this 302 report is free of any bias that might be associated with the commercial goals of the company. None 303 of the remaining co-authors has any potential financial conflict of interest related to the manuscript to 304 disclose. 305 306 
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